People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MindImmune Therapeutics, Inc. | — | Pharmaceuticals | Series B | $21.3M | $61.3M | 2025 |
| Octagon Therapeutics, Inc. | — | Pharmaceuticals | Series A | $12.4M | $68.3M | 2018 |
Isaac Stoner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac Stoner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher O'Donnell | 1 | 8 |
| Robert Nelson | 1 | 7 |
| Tracy Saxton | 1 | 5 |
| Thorne Sparkman | 1 | 5 |
| Paul Goldenheim | 1 | 3 |
| Ronald Lennox | 1 | 3 |
| Richard G. Horan | 1 | 2 |
| Fred Ausubel | 1 | 1 |
| Shen Yu | 1 | 1 |
| Reetika Bhardwaj | 1 | 1 |
| Bradley Margus | 1 | 1 |
| Robert B. Nelson | 1 | 1 |
| Stevin Zorn | 1 | 1 |
| Diane Gooding | 1 | 1 |
| Frank S. Menniti | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.